Schimanski C C, Linnemann U, Berger M R
Unit of Toxicology and Chemotherapy, German Cancer Research Center, Heidelberg, Germany.
Cancer Res. 1999 Oct 15;59(20):5169-75.
Postoperative survival of colorectal cancer patients is often delineated by metastases spreading to the liver. Current clinical diagnostic procedures are unable to discover micrometastases in this organ. Our aim was to develop a diagnostic tool for detecting micrometastases that are present at the time of surgery. Therefore, a PCR-RFLP assay was set up tracking point mutations of the K-ras oncogene at codons 12 and 13, based on mismatch primers and restriction enzymes BstXI and XcmI. The detection limit of this assay was one mutant in one million wild-type cells. One hundred forty-two patients with colorectal carcinoma were screened for these mutations in tissue samples from their tumor, proximally adjacent mucosa, and liver. Of these, 67 patients (46%) were positive for a K-ras mutation, of which 58 had codon 12 and 9 had codon 13 mutations. No patient without a K-ras-positive tumor showed a mutation in mucosa, but 11 patients with a K-ras-positive tumor (11 of 58; 19%) were found to bear a K-ras mutation in their mucosa, and in 21 patients (21 of 64; 33%), a K-ras mutation was detected in liver tissue. Sequencing of all mutated samples revealed a 92% confirmation of PCR-RFLP results. In summary, the assay is a useful tool for detecting K-ras codon 12 and 13 mutations and allows early proof of molecular determinants of liver metastases. Such knowledge will improve the staging of colorectal cancer patients and could beneficially influence their prognosis if followed by an effective therapy.
结直肠癌患者的术后生存率常因癌细胞转移至肝脏而受到影响。目前的临床诊断方法无法检测出该器官中的微转移灶。我们的目标是开发一种诊断工具,用于检测手术时存在的微转移灶。因此,基于错配引物以及限制性内切酶BstXI和XcmI,建立了一种PCR-RFLP分析方法,用于追踪K-ras癌基因第12和13密码子的点突变。该分析方法的检测限为百万个野生型细胞中有一个突变体。对142例结直肠癌患者的肿瘤组织、近端相邻黏膜组织和肝脏组织样本进行了这些突变的筛查。其中,67例患者(46%)的K-ras基因发生突变,其中58例为第12密码子突变,9例为第13密码子突变。K-ras基因肿瘤阴性的患者,其黏膜组织未发现突变,但11例K-ras基因肿瘤阳性的患者(58例中的11例;19%)的黏膜组织存在K-ras基因突变,21例患者(64例中的21例;33%)的肝脏组织检测到K-ras基因突变。对所有突变样本进行测序,结果显示PCR-RFLP结果的确认率为92%。总之,该分析方法是检测K-ras基因第12和13密码子突变的有用工具,能够早期证实肝转移的分子决定因素。这些信息将改善结直肠癌患者的分期,如果后续采用有效治疗,可能会对其预后产生有益影响。